Journal of Clinical Epidemiology
Volume 63, Issue 2 , Pages 128-129 , February 2010

Pharmaceutical company–sponsored drug trials: the system is broken

  • Gerald Gartlehner

      Affiliations

    • Corresponding Author InformationCorresponding author. Department for Evidence-based Medicine and Clinical Epidemiology, Danube University, Krems, Austria.

,Accepted 31 July 2009.

References 

  1. Gartlehner G, Morgan L, Thieda P, Fleg A. The effect of study sponsorship on a systematically evaluated body of evidence of head-to-head trials was modest: secondary analysis of a systematic review. J Clin Epidemiol. 2010;63:117–125[in this issue]
  2. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252–260
  3. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45
  4. Barden J, Derry S, McQuay HJ, et al. Bias from industry trial funding? A framework, a suggested approach, and a negative result. Pain. 2006;121:207–218
  5. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–2346
  6. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  7. The Health Effects Institute. 2009 Accessed June 15, 2009]; Available at: http://www.healtheffects.org/pubs.htm.

PII: S0895-4356(09)00229-7

doi: 10.1016/j.jclinepi.2009.07.015

Journal of Clinical Epidemiology
Volume 63, Issue 2 , Pages 128-129 , February 2010

Article Tools